Literature DB >> 32006697

Follow-up blood cultures are associated with improved outcome of patients with gram-negative bloodstream infections: retrospective observational cohort study.

M Giannella1, R Pascale2, L Pancaldi1, C Monari3, S Ianniruberto1, P Malosso1, L Bussini1, M Bartoletti1, S Tedeschi1, S Ambretti4, R Lewis1, P Viale1.   

Abstract

OBJECTIVES: We examined factors associated with follow-up blood cultures (FUBCs) in patients with monomicrobial Gram-negative (GN) bloodstream infection (BSI) and investigated the impact of FUBCs on therapeutic management and patient outcome.
METHODS: A retrospective cohort analysis was conducted of adult patients diagnosed with GN-BSI at a tertiary-care university hospital during 2013-2016. FUBCs performed between 24 hours and 7 days after index BCs was the exposure variable. Risk factors for 30-day mortality were analysed by multivariate Cox analysis on the overall cohort, including FUBCs as a time-varying covariate and on 1:1 matched patients according to Sequential Organ Failure Assessment (SOFA) score and time to FUBC.
RESULTS: In 278 (17.6%) of 1576 patients, FUBCs were performed within a median of 3 and 2 days after index BCs and active antibiotic therapy initiation. Persistent BSI was found in 107 (38.5%) of 278 patients. FUBCs were performed in more severely ill patients, with nonurinary sources, difficult-to-treat pathogens and receipt of initial inappropriate therapy. Source control and infectious disease consultation rates were higher among patients with preceding FUBCs and was associated with longer treatment duration. Thirty-day mortality was 10.4%. Independent risk factors for mortality were Charlson comorbidity index (hazard ratio (HR) 1.12) SOFA (HR 1.11), septic shock (HR 2.64), urinary source (HR 0.60), central venous catheter source (HR 2.30), complicated BSI (HR 2.10), carbapenem resistance (HR 2.34), active empiric therapy (HR 0.68), source control (HR 0.34) and FUBCs (HR 0.48). Association between FUBCs and lower mortality was confirmed in the 274 matched pairs.
CONCLUSIONS: FUBCs were performed in more severe GN-BSIs, yielding a high rate of persistent BSI. In this context, FUBCs were associated with lower mortality.
Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  All-cause 30-day mortality; Bacteremia management; Bloodstream infection; Enterobacteriaceae; Follow-up blood cultures; Gram negative; Nonfermentative Gram negative

Year:  2020        PMID: 32006697     DOI: 10.1016/j.cmi.2020.01.023

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  9 in total

1.  Follow-up Blood Culture Practices for Gram-Negative Bloodstream Infections in Immunocompromised Hosts at a Large Academic Medical Center.

Authors:  Lauren Groft Buzzalino; James Mease; Ciera L Bernhardi; Jacqueline T Bork; J Kristie Johnson; Kimberly C Claeys
Journal:  Open Forum Infect Dis       Date:  2022-04-15       Impact factor: 4.423

2.  Impact of a Multistep Bundles Intervention in the Management and Outcome of Gram-Negative Bloodstream Infections: A Single-Center "Proof-of-Concept" Study.

Authors:  Davide Fiore Bavaro; Lucia Diella; Alessandra Belati; Nicolò De Gennaro; Deborah Fiordelisi; Roberta Papagni; Giacomo Guido; Elda De Vita; Luisa Frallonardo; Michele Camporeale; Carmen Pellegrino; Sofia Denicolò; Enrica Ranieri; Michele Fabiano Mariani; Gaetano Brindicci; Luigi Ronga; Francesco Di Gennaro; Adriana Mosca; Annalisa Saracino
Journal:  Open Forum Infect Dis       Date:  2022-09-17       Impact factor: 4.423

3.  Predictive scoring models for persistent gram-negative bacteremia that reduce the need for follow-up blood cultures: a retrospective observational cohort study.

Authors:  Jongtak Jung; Kyoung-Ho Song; Kang Il Jun; Chang Kyoung Kang; Nak-Hyun Kim; Pyoeng Gyun Choe; Wan Beom Park; Ji Hwan Bang; Eu Suk Kim; Sang-Won Park; Nam Joong Kim; Myoung-Don Oh; Hong Bin Kim
Journal:  BMC Infect Dis       Date:  2020-09-17       Impact factor: 3.090

Review 4.  Are Follow-Up Blood Cultures Useful in the Antimicrobial Management of Gram Negative Bacteremia? A Reappraisal of Their Role Based on Current Knowledge.

Authors:  Francesco Cogliati Dezza; Ambrogio Curtolo; Lorenzo Volpicelli; Giancarlo Ceccarelli; Alessandra Oliva; Mario Venditti
Journal:  Antibiotics (Basel)       Date:  2020-12-11

5.  Impact of follow up blood cultures on outcomes of patients with community-onset gram-negative bloodstream infection.

Authors:  Rajiv Amipara; Hana Rac Winders; Julie Ann Justo; P Brandon Bookstaver; Joseph Kohn; Majdi N Al-Hasan
Journal:  EClinicalMedicine       Date:  2021-03-30

6.  Survey of infectious diseases providers reveals variability in duration of antibiotic therapy for the treatment of Gram-negative bloodstream infections.

Authors:  Joshua T Thaden; Pranita D Tamma; Qing Pan; Yohei Doi; Nick Daneman
Journal:  JAC Antimicrob Resist       Date:  2022-02-09

7.  Routine laboratory biomarkers used to predict Gram-positive or Gram-negative bacteria involved in bloodstream infections.

Authors:  Daniela Dambroso-Altafini; Thatiany C Menegucci; Bruno B Costa; Rafael R B Moreira; Sheila A B Nishiyama; Josmar Mazucheli; Maria C B Tognim
Journal:  Sci Rep       Date:  2022-09-14       Impact factor: 4.996

8.  Follow-up blood cultures in Pseudomonas aeruginosa bacteremia: A potential target for diagnostic stewardship.

Authors:  Alexis L Green; Yuanyuan Liang; Lyndsay M O'Hara; Lisa Pineles; Scott Sorongon; Anthony D Harris; Jonathan D Baghdadi
Journal:  Antimicrob Steward Healthc Epidemiol       Date:  2021-08-27

9.  Association of Follow-up Blood Cultures With Mortality in Patients With Gram-Negative Bloodstream Infections: A Systematic Review and Meta-analysis.

Authors:  Joshua T Thaden; Sarah Cantrell; Michael Dagher; Yazhong Tao; Felicia Ruffin; Stacey A Maskarinec; Stacy Goins; Matthew Sinclair; Joshua B Parsons; Emily Eichenberger; Vance G Fowler
Journal:  JAMA Netw Open       Date:  2022-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.